Abstract title: “Sotatercept, an Activin Receptor-2a Ligand Trap, Modulates Hepcidin Levels in Primary Human Hepatocytes”Abstract number: 3441Session: 102. Regulation of Iron Metabolism: Poster IIIDate: Monday, December 9, 2013Time: 6:00 PM – 8:00 PM CST (Ernest N. Morial Convention Center, Hall E)Abstract title: “RAP-011 Efficiently Rescues Erythropoiesis in Zebrafish Models of Diamond Blackfan Anemia”Abstract number: 3702Session: 508. Bone Marrow Failure: Poster IIIDate: Monday, December 9, 2013Time: 6:00 PM – 8:00 PM CST (Ernest N. Morial Convention Center, Hall E) ACE- 536 Preclinical Data Abstract title: “Modified Activin Receptor Type IIb-Fc Fusion Protein (RAP-536) Decreases Anemia in a Murine Model of Myelodysplastic Syndrome and Improves Overall Survival”Abstract number: 749Date: Monday, December 9, 2013Session: 633. Myelodysplastic Syndromes: Basic and Clinical InsightsTime: Oral presentation at 7:15 PM CST (New Orleans Theater AB) About Sotatercept and ACE-536 Sotatercept is an activin receptor type IIA fusion protein and ACE-536 is a modified activin receptor type IIB fusion protein. Both molecules act as ligand traps for members of the TGF-β superfamily involved in the late stages of erythropoiesis (red blood cell production). Sotatercept and ACE-536 regulate late-stage erythrocyte (red blood cell) precursor cell differentiation and maturation. This mechanism of action is distinct from that of erythropoietin (EPO), which stimulates the proliferation of early-stage erythrocyte precursor cells. Diseases like myelodysplastic syndromes (MDS) and beta-thalassemia are characterized by “ineffective erythropoiesis,” in which there is an over-production of early-stage erythrocyte precursors in the bone marrow and premature apoptosis (cell death) of later-stage precursors. Administration of EPO does not correct the underlying cause of the anemia associated with ineffective erythropoiesis. By promoting the differentiation of later-stage erythroid precursor cells into mature red blood cells, sotatercept and ACE-536 address the ineffective erythropoiesis and therefore have the potential to treat the anemia underlying both MDS and beta-thalassemia. Acceleron and Celgene are jointly developing sotatercept and ACE-536. Both molecules are currently in phase 2 clinical trials in patients with beta-thalassemia and in patients with MDS. For more information, please visit www.clinicaltrials.gov. About Acceleron Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-β) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases.
For more information, please visit www.acceleronpharma.com.